reports
HANSOH PHARMACEUTICAL GROUP reduces its risk exposure and slightly imp...
The independent financial analyst theScreener just allocated a lower risk rating to HANSOH PHARMACEUTICAL GROUP (HK), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date March 1, 2022, the closing price was HKD 16.80 and...
- Valens Research
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.